Approximately one in four people in the UK experience mental health concerns each year. While advances in mental health research are being made, there remain significant barriers to effective detection, treatment and prevention.
A spinout from the University of Cambridge, Psyomics is looking to overcome these barriers by combining digital approaches with developments in biomarker technology to benefit those facing mental health challenges. The tools currently in development are targeted for both clinical and workplace settings, specifically designed to combat the respective mental health-related challenges faced within these environments. In the future, we plan to expand our reach to provide personalised solutions for the wider community.
Psyomics was founded in 2015 by Professor Sabine Bahn, who has dedicated more than 20 years of research to identifying differential biomarkers of mental health symptoms. Our work is funded and supported by Cambridge Enterprise and a Horizon 2020 grant from the European Commission. In addition, Psyomics won an innovation contest with IC Tomorrow and AXA PPP to look at mental health awareness and prevention in the workplace, and won the Problem Solution category of the AXA PPP Health Tech & You Awards. We have also recently been awarded a grant from the Technology Strategy Board to further develop its technology for differentiating bipolar disorder from depression.
Accurate and early diagnosis is essential for the effective treatment of mental illnesses, but many individuals are only correctly diagnosed after having struggled with debilitating symptoms for many years. Research has repeatedly shown that the current reliance on obtaining diagnoses through clinical interviews, and the constraints of short appointment times means that all too often a patient’s symptoms can be misidentified or even missed altogether.
Psyomics is attempting to provide a solution to this problem in collaboration with scientists from the Cambridge Centre for Neuropsychiatric Research. Through this partnership, we are developing an innovative diagnostic tool, which combines biological information with digital information collected through a web-based app. This can be utilised by patients within the privacy of their own homes, and at their own pace, facilitating faster, more accurate clinical diagnoses, which enable them to receive the best treatment interventions as soon as possible.Find Out More
Nearly a quarter of us will face a mental health challenge at some point in our lives. But just as early detection gives cancer patients a better chance of beating their disease, the same is true for mental health. Scientific studies have indicated that early diagnosis of disorders such as depression and anxiety, either through detecting underlying biological changes or shifts in sleep patterns, energy levels, mindset and stress levels, can lead to more effective treatment and reduce the likelihood of relapse.
Through biological research and advances in mobile technology, Psyomics is developing tools to facilitate the detection and monitoring of mental health challenges at an early - perhaps even pre-clinical - stage, increasing the chances of successful treatment. In addition, our tools are designed using research-driven strategies to provide anyone concerned about their mental health with personalized feedback, information, and recommendations for self-help or treatment options. In this way, we hope to empower individuals to take control of their own mental health, improving day-to-day psychological resilience and thus reducing vulnerability to mental health deterioration.Find Out More
Psyomics brings together a diverse group of experts spanning the scientific, clinical, and business worlds, ranging from leaders in commercial healthcare, to consultant psychiatrists and cutting edge translational scientists. This breadth of experience and skill sets across different specialist areas in the worlds of biotech and mental health are what makes Psyomics an innovative and dynamic team, enabling us to deliver on our promise to facilitate better outcomes in mental health. Our advisory board includes not only clinicians, but patients and carers themselves, to ensure that patient needs remain at the forefront of the tools we are developing.Find Out More
At Psyomics, digital security is one of our core concerns; we believe that our customers’ trust is a privilege that cannot be taken for granted. We adhere to industry best-practices throughout the development of all products; our software products have received medical device certification - reflecting the highest industry standards - and all technology offerings are thoroughly reviewed by our highly-qualified regulatory team. Furthermore, our research upholds the highest ethical and regulatory standards - a philosophy we endeavour to pursue in all of our future projects.Find Out More